Abstract：Objective To explore the clinical efficacy of grafting treatment of stable vitiligo with ReCell technology.Methods Twenty-one patients of stable vitiligo were selected between 2015 and 2017. The melanocytes were taken from suction skin blisters on the abdomen wall. The non-cultured melanocyte-keratinocyte suspension was prepared with ReCell technology before the cell suspension was grafted onto vitiliginous lesions.Results Thirty lesions from 21 vitiligo patients were treated with cell suspension grafting. There was repigmentation to different extents in all the patients after operation. The total rate of repigmentation of grade 3 to 4 was 87.09% after six months.Conclusions When ReCell technology is used for grafting treatment of vitiligo, the repigmentation efficacy is excellent, and no scar is formed in suction blisters. This approach is relatively simple and reliable without the need for a special laboratory.
Cervelli V, De Angelis B, Spallone D, et al. Treatment of stable vitiligo by ReCell system: a preliminary report[J]. Eur Rev Med Pharmacol Sci, 2010, 14(8): 691-694.
Wood F M, Giles N, Stevenson A, et al. Characterisation of the cell suspension harvested from the dermal epidermal junction using a ReCell kit[J]. Burns, 2016, 38(1): 44-51.
[5]
Hong W S, Hu D N, Qian G P, et al. Treatment of vitiligo in children and adolescents by autologous cultured pure melanocytes transplantation with comparison of efficacy to results in adults[J]. J Eur Acad Dermatol Venereol, 2011, 25(5): 38-543.
2019, Vol. 30 
